CLL/MCL Coverage from Every Angle
Editor:
Jeremy S. Abramson, MD, MMSc
Advertisement
Advertisement

News

Venetoclax/Obinutuzumab May Improve PFS in CLL
Mantle Cell Lymphoma: Comparing Outcomes With Time-Limited Initial Regimens
Factors Impacting Overall Survival Among Patients With CLL on Targeted Therapy
Early Results With Single-Agent Epcoritamab in Resistant CLL
Relapsed Mantle Cell Lymphoma: Treatment Strategies After CAR T-Cell Therapy
Early Research Findings on the Use of Zanubrutinib Plus Sonrotoclax in CLL
Long-Term Outcomes With Induction Therapies for Mantle Cell Lymphoma
Updates From TRANSCEND CLL 004: Use of Lisocabtagene Maraleucel in CLL or SLL
AMPLIFY Trial Investigates Triplet Immunotherapy vs Chemoimmunotherapy in CLL
OASIS II: Triplet Immunotherapy Regimen for Treatment-Naive MCL
Combining Acalabrutinib and Rituximab in Older Patients With Mantle Cell Lymphoma
BRUIN CLL-321 Trial: Update on Pirtobrutinib for BTK Inhibitor–Pretreated CLL or SLL
Combination of Lisocabtagene Maraleucel and Ibrutinib in Aggressive CLL or SLL
Activity of Novel Antibody-Drug Conjugate in Resistant Mantle Cell Lymphoma
Acalabrutinib-Based Combination Under Study in Previously Untreated CLL
Diagnostic and Insurance Disparities Among Minority Patients With Lymphoma
European Study on Chemoimmunotherapy vs BTK Inhibitors in CLL
Use of ASCT in Patients With Mantle Cell Carcinoma in Complete Remission
NCCN Announces Grants Awarded to Quality Improvement Research Projects in CLL/SLL
Can Venetoclax Boost Response to CAR T-Cell Therapy in CLL?
New Standard of Care for Older Patients With Mantle Cell Lymphoma?
Long-Term Outcomes of CAR T-Cell Therapy in Responders With CLL
Novel BTK Inhibitor–Based Combination First-Line Treatment of CLL
Triplet Regimen Under Study in Untreated CLL
Impact of Immunosenescence on CAR T-Cell Treatment in CLL
ZUMA-2 Trial Supports Brexucabtagene Autoleucel in BTK Inhibitor–Naive Relapsed or Refractory MCL
Adding BTK Inhibitor to Chemoimmunotherapy in Mantle Cell Lymphoma
Factors Influencing CAR T-Cell Therapy Outcomes in Recurrent Mantle Cell Lymphoma
Is ASCT Necessary After Ibrutinib Treatment in Mantle Cell Lymphoma?
Acalabrutinib Combination Therapy Approved by FDA for Previously Untreated MCL
Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.